Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography
Open Access
- 11 December 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 116 (3) , 479-482
Abstract
Light liquid paraffin (pharmaceutical grade mineral oil) has been used as a placebo in clinical trials of icosapent ethyl including MARINE, ANCHOR, and REDUCE-IT. Pharmaceutical grade mineral oil (distinct from technical/industrial or food grade mineral oils) was chosen as a suitable placebo to mimic the consistency, colour, and odourless properties of icosapent ethyl capsules. Since the results of REDUCE-IT, a few have raised questions regarding possible biological activity of mineral oil placebo due to small changes in some cardiac biomarkers including lipid levels and inflammatory markers in placebo arm patients, asking whether the mineral oil utilized in placebo capsules was physiologically inert or not. 1 Mineral oil has been utilized in humans as a laxative for decades (typically in doses of 15–45 g/day), and the general safety has been inferred from clinical utilization. The ∼2 g twice per day of light liquid mineral oil taken by placebo group patients in clinical trials equates to less than a teaspoon per day.Keywords
Funding Information
- EVAPORATE
This publication has 14 references indexed in Scilit:
- Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE studyClinical Cardiology, 2018
- Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical TrialJournal of the American Heart Association, 2017
- Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low TestosteroneJAMA, 2017
- Aged Garlic Extract Reduces Low Attenuation Plaque in Coronary Arteries of Patients with Metabolic Syndrome in a Prospective Randomized Double-Blind StudyThe Journal of Nutrition, 2016
- Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesionsEuropean Heart Journal, 2016
- Plaque Characterization by Coronary Computed Tomography Angiography and the Likelihood of Acute Coronary Events in Mid-Term Follow-UpJACC, 2015
- Differences in Prevalence, Extent, Severity, and Prognosis of Coronary Artery Disease Among Patients With and Without Diabetes Undergoing Coronary Computed Tomography AngiographyDiabetes Care, 2012
- Treatment for 2 mo with n−3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled studyThe American Journal of Clinical Nutrition, 2007
- Reduction in Triglyceride Level With N-3 Polyunsaturated Fatty Acids in HIV-Infected Patients Taking Potent Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialThe Lancet, 2004